MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-08-2026
Mettler-Toledo International Retained Earnings 2011-2026 | MTD
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Mettler-Toledo International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.24 B | 8.37 B | 7.51 B | 6.73 B | 5.86 B | 5.1 B | 4.5 B | 3.94 B | 3.43 B | 3.07 B | 2.69 B | 2.36 B | 2.04 B | 1.75 B | 1.48 B | 1.22 B | 1.01 B | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.24 B | 1.01 B | 4.13 B |
Quarterly Retained Earnings Mettler-Toledo International
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.41 B | 8.95 B | 8.74 B | 8.53 B | 8.37 B | 8.12 B | 7.91 B | - | 7.51 B | 7.33 B | 7.13 B | 6.91 B | 6.73 B | 6.46 B | - | 6.03 B | 5.86 B | 5.63 B | 5.43 B | 5.24 B | 5.1 B | 5.1 B | 5.1 B | 5.1 B | 4.5 B | 4.5 B | 4.5 B | 4.5 B | 3.94 B | 3.94 B | 3.94 B | 3.94 B | 3.43 B | 3.43 B | 3.43 B | 3.16 B | 3.07 B | 3.07 B | 3.07 B | 3.07 B | 2.69 B | 2.69 B | 2.69 B | 2.69 B | 2.36 B | 2.36 B | 2.36 B | 2.36 B | 2.04 B | 2.04 B | 2.04 B | 2.04 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B | 1.15 B | 1.09 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.41 B | 1.09 B | 4.23 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B |  USA |
 |
Agilent Technologies
A
|
348 M | $ 135.53 | 0.11 % | $ 41.2 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 132.88 | 1.5 % | $ 6.21 B | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 8.53 | -23.77 % | $ 11.3 M | USA |
 |
Castle Biosciences
CSTL
|
-224 M | $ 21.08 | -4.66 % | $ 611 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-719 M | - | -61.36 % | $ 2.46 M | USA |
 |
Fulgent Genetics
FLGT
|
530 M | $ 18.14 | -0.55 % | $ 558 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 129.69 | -2.65 % | $ 16.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
-735 M | $ 22.82 | 0.53 % | $ 1.22 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.12 B | $ 136.07 | -0.53 % | $ 10.7 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
-166 M | - | - | $ 9.42 M |  Israel |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.7 | -5.56 % | $ 7.52 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 162.96 | 2.68 % | $ 25.9 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 99.3 | -0.32 % | $ 6.7 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-166 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 180.71 | -0.35 % | $ 8.96 B | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 10.52 | 3.24 % | $ 1.35 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 19.53 | -0.66 % | $ 437 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 223.37 | 4.41 % | $ 22 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 447.11 | -0.23 % | $ 12.9 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 3.97 | -5.92 % | $ 368 M | USA |
 |
Personalis
PSNL
|
-631 M | $ 11.4 | 3.83 % | $ 1.02 B | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 6.79 | 1.04 % | $ 283 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Soleno Therapeutics
SLNO
|
-431 M | - | - | $ 2.69 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 66.87 | -3.13 % | $ 4 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.39 | -1.74 % | $ 5.49 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 260.06 | -0.75 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 492.51 | 1.09 % | $ 186 B | USA |
 |
Trinity Biotech plc
TRIB
|
-79.1 M | $ 0.7 | -0.16 % | $ 251 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-536 M | $ 8.97 | -3.55 % | $ 1.95 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 194.9 | -0.72 % | $ 21.6 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |